Oleg Akilov

List of Publications by Year
in descending order

110	3,406	236833	155592
papers	citations	25 h-index	55 g-index

112	112	112	3804
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cutaneous metastasis of primary diffuse large Bâ€cell lymphoma of the central nervous system developing 4â€‰years after complete remission: Diagnosis confirmed by comparison of clones. Journal of Cutaneous Pathology, 2022, 49, 90-94.	0.7	1
2	The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. Cancer Immunology, Immunotherapy, 2022, 71, 919-932.	2.0	4
3	Effective treatment of mogamulizumab-induced head and neck dermatitis withÂfluconazole in a patient with peripheral T-Cell lymphoma. JAAD Case Reports, 2022, 20, 44-46.	0.4	1
4	Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma. Cells, 2022, 11, 593.	1.8	6
5	Repetitive expanded Tâ€cell receptor clonotypes impart the classic T helper 2 SÃ©zary cell phenotype. British Journal of Dermatology, 2022, 187, 265-267.	1.4	1
6	Exhausted Markers in Cutaneous T-Cell Lymphoma: The Face that Launched a Thousand Ships. Journal of Investigative Dermatology, 2022, 142, 512-515.	0.3	0
7	HSR22-182: Real-World Treatment Patterns Among Patients With SÃ©zary Syndrome in the United States Between 2018 and 2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, HSR22-182.	2.3	0
8	Real-world treatment patterns in patients with SÃ©zary syndrome in the United States and the impact of Covid-19.. Journal of Clinical Oncology, 2022, 40, e19578-e19578.	0.8	0
9	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. British Journal of Dermatology, 2021, 184, 722-730.	1.4	39
10	Should we be imaging lymph nodes at initial diagnosis of earlyâ€stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. British Journal of Dermatology, 2021, 184, 524-531.	1.4	18
11	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research, 2021, 27, 2190-2199.	3.2	110
12	The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal of Clinical Dermatology, 2021, 22, 407-414.	3.3	24
13	Response to brentuximab vedotin versus physicianâ€™s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. European Journal of Cancer, 2021, 148, 411-421.	1.3	27
14	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicianâ€™s choice in cutaneous T-cell lymphoma: final data. Blood Advances, 2021, 5, 5098-5106.	2.5	46
15	Research Techniques Made Simple: Skin-Targeted DrugÂand Vaccine Delivery Using Dissolvable Microneedle Arrays. Journal of Investigative Dermatology, 2021, 141, 2549-2557.e1.	0.3	1
16	Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or SÃ©zary syndrome: a multicentre, phase 1 study. Lancet Haematology,the, 2021, 8, e808-e817.	2.2	42
17	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2021, 138, 2448-2448.	0.6	6
18	Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides. Cancers, 2021, 13, 5982.	1.7	7

#	Article	IF	Citations
19	Characteristics associated with significantly worse quality of life in mycosis fungoides/SÃ©zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index () Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 7	1.4	72
20	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of the American Academy of Dermatology, 2020, 82, 366-376.	0.6	165
21	The Utility of T-Cell Clonality in Differential Diagnostics of Acute Graft-versus-Host Disease from Drug Hypersensitivity Reaction. Journal of Investigative Dermatology, 2020, 140, 1282-1285.	0.3	6
22	The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1. Blood Advances, 2020, 4, 4788-4797.	2.5	9
23	17910 Using clonality of T-cell repertoire to distinguish between drug hypersensitivity reaction and acute graft-versus-host disease. Journal of the American Academy of Dermatology, 2020, 83, AB87.	0.6	0
24	AML-373: Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S209-S210.	0.2	1
25	TCL-127: Impact of Concomitant Steroids on Mogamulizumab Efficacy in MAVORIC. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S252-S253.	0.2	1
26	æ·è‚‰èŠ½è‚¿å'Œ SÃ©zary ç»¼å•å¾æ£è€…ç"Ÿæ´»è¨é‡ç©¶. British Journal of Dermatology, 2020, 182, e109.	1.4	0
27	Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma. Blood, 2020, 136, 1748-1759.	0.6	25
28	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European Journal of Cancer, 2020, 133, 120-130.	1.3	21
29	A study of quality of life in people with mycosis fungoides and SÃ©zary syndrome. British Journal of Dermatology, 2020, 182, e96.	1.4	0
30	United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 83, 703-704.	0.6	22
31	The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-Life Clinical Data. Acta Dermato-Venereologica, 2020, 100, adv00277.	0.6	8
32	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2020, 136, 41-43.	0.6	5
33	Co-Inhibition of IL-2, IL-9 and IL-15 By the Novel Immunomodulator, Bnz-1, Provides Clinical Efficacy in Patients with Refractory Cutaneous T Cell Lymphoma in a Phase 1/2 Clinical Trial. Blood, 2020, 136, 37-37.	0.6	2
34	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). Hematological Oncology, 2019, 37, 286-288.	0.8	2
35	Defining B2 involvement in Sezary syndrome results from the PROCLIPI study. European Journal of Cancer, 2019, 119, S6.	1.3	0
36	Prognostic factors in mycosis fungoides: the PROCLIPI study. European Journal of Cancer, 2019, 119, S26.	1.3	1

#	Article	IF	Citations
37	Brentuximab vedotin (BV) versus physicianâ€™s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides) Tj ETQq1 1 0.784314 rgBT /Overlo results from the phase 3 ALCANZA study. European Journal of Cancer, 2019, 119, S31.	1.3	1
38	Anti-CD7 immunotherapy is mediated by cytotoxic CD107a+IFN-Î³â€“ NK cells and can be potentiated by interferon-Î± in cutaneous lymphoma. European Journal of Cancer, 2019, 119, S33.	1.3	1
39	An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study. European Journal of Cancer, 2019, 119, S38-S39.	1.3	0
40	Blocking TNF-Î±/Th17 pathway with monoclonal cytokine antibodies may aggravate the course of mycosis fungoides: a multicenter retrospective analysis of real-world clinical data. European Journal of Cancer, 2019, 119, S42.	1.3	0
41	Treatment of early-phase mycosis fungoides: results from the Prospective Cutaneous Lymphoma International (PROCLIPI) study. European Journal of Cancer, 2019, 119, S27.	1.3	0
42	LB1060 Cytokine profile of SÃ©zary Syndrome in relationship with expression of checkpoint inhibitors on SÃ©zary cells. Journal of Investigative Dermatology, 2019, 139, B4.	0.3	0
43	T-cell receptor rearrangements in the skin and blood of patients in the PROCLIPI study: detection of clonal rearrangements in the skin (and blood) correlates with the B-class of MF and SS patients. European Journal of Cancer, 2019, 119, S25.	1.3	0
44	Nail Changes in SÃ©zary Syndrome: A Single-Center Study and Review of the Literature. Journal of Cutaneous Medicine and Surgery, 2019, 23, 380-387.	0.6	8
45	Targeting CD47 in SÃ©zary syndrome with SIRPÎ±Fc. Blood Advances, 2019, 3, 1145-1153.	2.5	77
46	Rare Cutaneous T-Cell Lymphomas. Hematology/Oncology Clinics of North America, 2019, 33, 135-148.	0.9	12
47	The PROCLIPI international registry of earlyâ€stage mycosis fungoides identifies substantial diagnostic delay in most patients. British Journal of Dermatology, 2019, 181, 350-357.	1.4	127
48	Safety of Mogamulizumab in Mycosis Fungoides and SÃ©zary Syndrome: Final Results from the Phase 3 Mavoric Study. Blood, 2019, 134, 5300-5300.	0.6	3
49	Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget, 2019, 10, 3104-3113.	0.8	26
50	Interferon-Î±2b-induced STAT3 suppression in myeloid-derived suppressor cells in mycosis fungoides. Cancer Immunology, Immunotherapy, 2018, 67, 1177-1178.	2.0	1
51	Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Experimental Dermatology, 2018, 27, 188-190.	1.4	8
52	Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and SÃ©zary syndrome. Cancer Immunology, Immunotherapy, 2018, 67, 423-434.	2.0	23
53	The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. Journal of Dermatological Treatment, 2018, 29, 272-276.	1.1	15
54	A panel of three miRNAs in mycosis fungoides: a new prognostic tool?. Journal of Laboratory and Precision Medicine, 2018, 3, 41-41.	1.1	0

#	Article	IF	Citations
55	Onychodystrophy in SÃ©zary syndrome. Journal of the American Academy of Dermatology, 2018, 79, 972-973.	0.6	5
56	Lymph node imaging in patch/plaque mycosis fungoides; enlarged LN are infrequent but lymphomatous nodal involvement may occur and upstage patients to advanced disease. European Journal of Cancer, 2018, 101, S25-S26.	1.3	0
57	Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, SÃ©zary syndrome and those with more extensive skin involvement. European Journal of Cancer, 2018, 101, S39.	1.3	1
58	Phase 1, single-arm, open-label, dose escalation trial of microneedle array-doxorubicin in patients with mycosis fungoides. European Journal of Cancer, 2018, 101, S32.	1.3	2
59	Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and SÃ©zary syndrome: Interim results of a multicenter Phase 1 trial. European Journal of Cancer, 2018, 101, S34.	1.3	7
60	Dual-Positive CD4/CD8 Primary Cutaneous Peripheral T-Cell Lymphoma Previously Classified as Mycosis Fungoides a Tumor D'EmblÃ©e. American Journal of Dermatopathology, 2018, 40, 836-840.	0.3	2
61	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1192-1204.	5.1	398
62	Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPÎ±Fc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and SÃ©zary Syndrome: Interim Results of a Multicenter Phase I Trial. Blood, 2018, 132, 1653-1653.	0.6	11
63	Cutaneous T-cell lymphomas: modern data of pathogenesis, clinics and therapy. Oncogematologiya, 2018, 13, 25-38.	0.1	2
64	Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study. Blood, 2018, 132, 1646-1646.	0.6	0
65	The biomarker landscape in mycosis fungoides and SÃ©zary syndrome. Experimental Dermatology, 2017, 26, 668-676.	1.4	26
66	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, The, 2017, 390, 555-566.	6.3	444
67	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. Hematological Oncology, 2017, 35, 245-247.	0.8	1
68	PATIENTâ€REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. Hematological Oncology, 2017, 35, 247-248.	0.8	2
69	Hypopigmented Mycosis Fungoides with Large Cell Transformation in a Child. Pediatric Dermatology, 2017, 34, e260-e264.	0.5	4
70	A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.. Journal of Clinical Oncology, 2017, 35, TPS3101-TPS3101.	0.8	4
71	Romidepsin controls chronic lymphocytic leukemia in a patient with mycosis fungoides. Hematology Reports, 2016, 8, 6840.	0.3	3
72	Cutaneous Small/Medium CD4+ Pleomorphic T-Cell Lymphomaâ€“Like Nodule in a Patient With Erythema Chronicum Migrans. American Journal of Dermatopathology, 2016, 38, 448-452.	0.3	6

#	Article	IF	Citations
73	Interleukin-12 immunohistochemistry as a diagnostic tool for patch-stage mycosis fungoides. Journal of the American Academy of Dermatology, 2016, 75, 1053-1054.	0.6	2
74	CD56â˜' extranodal natural killer (NK)/T-cell lymphoma, nasal type presenting as skin ulcers in a white man. JAAD Case Reports, 2016, 2, 390-396.	0.4	7
75	Computer-aided classification of melanocytic lesions using dermoscopic images. Journal of the American Academy of Dermatology, 2015, 73, 769-776.	0.6	79
76	Photodynamic Therapy with 5% ^|^delta;-Aminolevulinic Acid is Safe and Effective Treatment of Acne Vulgaris in Japanese Patients. Laser Therapy, 2014, 23, 115-120.	0.8	18
77	Hair Follicle Nevus of the Abdominal Skin: An Unusual Extracephalic Presentation. Pediatric Dermatology, 2014, 31, e85-6.	0.5	7
78	Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Experimental Dermatology, 2014, 23, 598-600.	1.4	10
79	Bullous Sweet's Syndrome After Granulocyte Colonyâ€Stimulating Factor Therapy in a Child with Congenital Neutropenia. Pediatric Dermatology, 2014, 31, e61-2.	0.5	6
80	Non-random geographic distribution of patients with cutaneous T-cell lymphoma in the Greater Pittsburgh Area. Dermatology Online Journal, 2014, 20, .	0.2	27
81	Diagnostic Inaccuracy of Smartphone Applications for Melanoma Detection. JAMA Dermatology, 2013, 149, 422.	2.0	337
82	Immediate early response gene X-1, a potential prognostic biomarker in cancers. Expert Opinion on Therapeutic Targets, 2013, 17, 593-606.	1.5	20
83	Early scrotal approximation after hemiscrotectomy in patients with Fournierâ€™s gangrene prevents scrotal reconstruction with skin graft. Canadian Urological Association Journal, 2013, 7, 481.	0.3	21
84	Cutaneous Manifestations of Unspecified Peripheral T-Cell Lymphoma May Be Indicative of Disease Activity and Predict Response to Therapy. Journal of Clinical Oncology, 2012, 30, e283-e285.	0.8	5
85	Adverse Effects of Denileukin Diftitox and Their Management in Patients With Cutaneous T-Cell Lymphoma. Clinical Journal of Oncology Nursing, 2012, 16, E164-E172.	0.3	21
86	Resistance of SÃ©zary cells to TNFâ€Î±â€induced apoptosis is mediated in part by a loss of TNFR1 and a high level of the IER3 expression. Experimental Dermatology, 2012, 21, 287-292.	1.4	24
87	Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions. British Journal of Dermatology, 2012, 167, 194-197.	1.4	29
88	Vaccination with photodynamic therapyâ€treated macrophages induces highly suppressive Tâ€regulatory cells. Photodermatology Photoimmunology and Photomedicine, 2011, 27, 97-107.	0.7	12
89	Targeting of sebaceous glands by Î´â€aminolevulinic acidâ€based photodynamic therapy: An in vivo study. Lasers in Surgery and Medicine, 2011, 43, 376-381.	1.1	22
90	Clonal T-Cell Receptor Î³-Chain Gene Rearrangements in Differential Diagnosis of Lymphomatoid Papulosis From Skin Metastasis of Nodal Anaplastic Large-Cell Lymphoma. Archives of Dermatology, 2011, 147, 943.	1.7	5

#	Article	IF	Citations
91	Chapter 12. PDT for Cutaneous Leishmaniasis. Comprehensive Series in Photochemical and Photobiological Sciences, 2011, , 303-326.	0.3	1
92	Therapeutic advances in cutaneous T-cell lymphoma. Skin Therapy Letter, 2011, 16, 1-5.	0.3	5
93	Monitoring the efficacy of antimicrobial photodynamic therapy in a murine model of cutaneous leishmaniasis using L. major expressing GFP. Journal of Biophotonics, 2010, 3, 328-335.	1.1	17
94	Comparative splitâ€face study of 5â€aminolevulinic acid photodynamic therapy with intense pulsed light for photorejuvenation of Asian skin. Journal of Dermatology, 2010, 37, 1005-1010.	0.6	27
95	Enhanced Susceptibility toLeishmaniaInfection in Resistant Mice in the Absence of Immediate Early Response Gene X-1. Journal of Immunology, 2009, 183, 7994-8003.	0.4	19
96	Optimization of topical photodynamic therapy with 3,7â€bis(diâ€nâ€butylamino)phenothiazinâ€5â€ium bromide for cutaneous leishmaniasis. Lasers in Surgery and Medicine, 2009, 41, 358-365.	1.1	25
97	Photochemistry-based immune modulation in the treatment of cutaneous leishmaniasis. , 2009, , .		1
98	Prospects for the use of differentiationâ€modulating agents as adjuvant of photodynamic therapy for proliferative dermatoses. Journal of Dermatology, 2008, 35, 197-205.	0.6	11
99	The role of mannose receptor during experimental leishmaniasis. Journal of Leukocyte Biology, 2007, 81, 1188-1196.	1.5	52
100	Parasiticidal effect of Î´â€aminolevulinic acidâ€based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Experimental Dermatology, 2007, 16, 651-660.	1.4	100
101	Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. Photochemical and Photobiological Sciences, 2007, 6, 1067-1075.	1.6	61
102	Real-time fluorescence monitoring of phenothiazinium photosensitizers and their anti-mycobacterial photodynamic activity against Mycobacterium bovis BCG in in vitro and in vivo models of localized infection. Photochemical and Photobiological Sciences, 2007, 6, 1117.	1.6	39
103	A Mechanistic Study of Î´-Aminolevulinic Acid-Based Photodynamic Therapy for Cutaneous Leishmaniasis. Journal of Investigative Dermatology, 2007, 127, 1546-1549.	0.3	50
104	Clinical manifestations and classification of Old World cutaneous leishmaniasis. International Journal of Dermatology, 2007, 46, 132-142.	0.5	93
105	T helper type 1 cytokines and keratinocyte growth factor play a critical role in pseudoepitheliomatous hyperplasia initiation during cutaneous leishmaniasis. Archives of Dermatological Research, 2007, 299, 315-325.	1.1	17
106	Photoinactivation of Mycobacteria In Vitro and in a New Murine Model of Localized Mycobacterium bovis BCG-Induced Granulomatous Infection. Antimicrobial Agents and Chemotherapy, 2006, 50, 1828-1834.	1.4	73
107	The Role of Photosensitizer Molecular Charge and Structure on the Efficacy of Photodynamic Therapy against Leishmania Parasites. Chemistry and Biology, 2006, 13, 839-847.	6.2	68
108	Photodynamic therapy against intracellular pathogens: Problems and potentials. Medical Laser Application: International Journal for Laser Treatment and Research, 2006, 21, 251-260.	0.4	32

#	Article	IF	Citations
109	The Role of HLA A2 and Cw2 in the Pathogenesis of Human Demodicosis. Dermatology, 2005, 210, 109-114.	0.9	28
110	The potential for photodynamic therapy in the treatment of localized infections. Photodiagnosis and Photodynamic Therapy, 2005, 2, 247-262.	1.3	142